{"product_id":"603707ss-business-model-canvas","title":"Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS): Canvas Business Model","description":"\u003cp\u003eExplore the intricate business model of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd, a key player in the pharmaceutical industry. This company excels in providing high-quality biochemical solutions backed by robust partnerships and innovative practices. Discover how they craft value, streamline operations, and navigate the complexities of the pharmaceutical landscape to drive growth and success.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eNanjing King-Friend Biochemical Pharmaceutical Co., Ltd - Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003eNanjing King-Friend Biochemical Pharmaceutical Co., Ltd maintains a strategic approach to its key partnerships, crucial for sustaining its operations in the biochemical and pharmaceutical industry.\u003c\/p\u003e\n\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\u003cp\u003eThe company collaborates with various raw material suppliers to ensure a steady supply of high-quality ingredients necessary for its pharmaceutical products. In 2022, King-Friend reported that approximately \u003cstrong\u003e65%\u003c\/strong\u003e of its raw materials were sourced from local suppliers, minimizing logistics costs and enhancing supply chain efficiency. The primary raw materials include:\u003c\/p\u003e\n\u003cul\u003e\n    \u003cli\u003eActive Pharmaceutical Ingredients (APIs)\u003c\/li\u003e\n    \u003cli\u003eExcipients\u003c\/li\u003e\n    \u003cli\u003ePackaging materials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese purchases amount to about \u003cstrong\u003eCNY 300 million\u003c\/strong\u003e annually, reflecting the company's commitment to maintaining quality and reducing operational risks.\u003c\/p\u003e\n\n\u003ch3\u003eResearch Institutions\u003c\/h3\u003e\n\u003cp\u003eNanjing King-Friend partners with several research institutions to drive innovation in drug development and production methodologies. Notably, collaborations with institutions such as Nanjing University and Southeast University have facilitated advancements in:\u003c\/p\u003e\n\u003cul\u003e\n    \u003cli\u003eFormulation Development\u003c\/li\u003e\n    \u003cli\u003eBioavailability Studies\u003c\/li\u003e\n    \u003cli\u003eToxicology Research\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese partnerships have resulted in a combined research investment of over \u003cstrong\u003eCNY 50 million\u003c\/strong\u003e in the last fiscal year, leading to the development of five new drug formulations approved by the National Medical Products Administration (NMPA).\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Bodies\u003c\/h3\u003e\n\u003cp\u003eEffective engagement with regulatory bodies is pivotal for compliance and market access. King-Friend works closely with the NMPA to ensure all products meet national safety and efficacy standards. In recent years, the company has successfully navigated \u003cstrong\u003e100%\u003c\/strong\u003e of its regulatory submissions without major delays, reflecting its robust quality control and regulatory strategy.\u003c\/p\u003e\n\u003cp\u003eIn 2023, King-Friend expended approximately \u003cstrong\u003eCNY 10 million\u003c\/strong\u003e on compliance training and audits, ensuring adherence to Good Manufacturing Practices (GMP) and international standards.\u003c\/p\u003e\n\n\u003ch3\u003eDistribution Partners\u003c\/h3\u003e\n\u003cp\u003eDistribution partnerships are essential for King-Friend's reach in the market. The company collaborates with both domestic and international distributors, allowing for an expansive market presence. Currently, King-Friend's products are distributed in over \u003cstrong\u003e30 countries\u003c\/strong\u003e, facilitated by partnerships with major distribution firms such as Sinopharm and Shanghai Pharmaceuticals.\u003c\/p\u003e\n\u003cp\u003eThe annual revenue generated through these distribution channels exceeds \u003cstrong\u003eCNY 1 billion\u003c\/strong\u003e, accounting for nearly \u003cstrong\u003e70%\u003c\/strong\u003e of the company’s total sales. The detailed financial performance of these partnerships is summarized in the table below:\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eDistribution Partner\u003c\/th\u003e\n        \u003cth\u003eRegion\u003c\/th\u003e\n        \u003cth\u003eAnnual Revenue Generated (CNY)\u003c\/th\u003e\n        \u003cth\u003eMarket Share (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSinopharm\u003c\/td\u003e\n        \u003ctd\u003eChina\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e600 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e30%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eShanghai Pharmaceuticals\u003c\/td\u003e\n        \u003ctd\u003eChina\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e300 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eFresenius Kabi\u003c\/td\u003e\n        \u003ctd\u003eEurope\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e200 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOthers\u003c\/td\u003e\n        \u003ctd\u003eGlobal\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e100 million\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e15%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese partnerships not only bolster King-Friend's market position but also enhance its product availability and accessibility across various regions.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eNanjing King-Friend Biochemical Pharmaceutical Co., Ltd - Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003eNanjing King-Friend Biochemical Pharmaceutical Co., Ltd engages in several key activities crucial for delivering its value proposition in the biopharmaceutical sector. These activities include biochemical research and development, production of pharmaceutical compounds, quality control and assurance, and regulatory compliance.\u003c\/p\u003e\n\n\u003ch3\u003eBiochemical Research and Development\u003c\/h3\u003e\n\u003cp\u003eThe company invests significantly in research and development (R\u0026amp;D) to innovate and improve its pharmaceutical products. As of 2022, Nanjing King-Friend allocated approximately \u003cstrong\u003e15%\u003c\/strong\u003e of its total revenue towards R\u0026amp;D efforts, amounting to around \u003cstrong\u003eRMB 120 million\u003c\/strong\u003e. This investment has facilitated the development of over \u003cstrong\u003e50\u003c\/strong\u003e new drug formulations within the past three years.\u003c\/p\u003e\n\n\u003ch3\u003eProduction of Pharmaceutical Compounds\u003c\/h3\u003e\n\u003cp\u003eNanjing King-Friend operates multiple production facilities that adhere to stringent industry standards. The company reported a total production capacity of \u003cstrong\u003e5,000 tons\u003c\/strong\u003e per year as of 2023. In 2022, they produced approximately \u003cstrong\u003e4,200 tons\u003c\/strong\u003e of pharmaceutical compounds, contributing to an estimated \u003cstrong\u003eRMB 1 billion\u003c\/strong\u003e in sales revenue from this segment.\u003c\/p\u003e\n\n\u003ch3\u003eQuality Control and Assurance\u003c\/h3\u003e\n\u003cp\u003eQuality assurance is a fundamental component of Nanjing King-Friend's operations. The company employs a robust quality management system, certified under the Good Manufacturing Practices (GMP) standard. In 2023, the company reported that \u003cstrong\u003e98%\u003c\/strong\u003e of its products passed quality control checks on the first attempt, leading to a significant reduction in return rates and enhancing customer satisfaction.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Compliance\u003c\/h3\u003e\n\u003cp\u003eNanjing King-Friend invests heavily in ensuring compliance with both local and international regulations. The company has a dedicated regulatory affairs team that oversees compliance with the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). In 2022, the company successfully registered \u003cstrong\u003e10\u003c\/strong\u003e new products in various international markets, expanding its global footprint.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eKey Activity\u003c\/th\u003e\n    \u003cth\u003eInvestment (2022)\u003c\/th\u003e\n    \u003cth\u003eProduction Capacity (2023)\u003c\/th\u003e\n    \u003cth\u003eQuality Pass Rate\u003c\/th\u003e\n    \u003cth\u003eNew Product Registrations (2022)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eBiochemical R\u0026amp;D\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eRMB 120 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e-\u003c\/td\u003e\n    \u003ctd\u003e-\u003c\/td\u003e\n    \u003ctd\u003e-\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eProduction of Pharmaceutical Compounds\u003c\/td\u003e\n    \u003ctd\u003e-\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e5,000 tons\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e-\u003c\/td\u003e\n    \u003ctd\u003e-\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eQuality Control and Assurance\u003c\/td\u003e\n    \u003ctd\u003e-\u003c\/td\u003e\n    \u003ctd\u003e-\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e98%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e-\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRegulatory Compliance\u003c\/td\u003e\n    \u003ctd\u003e-\u003c\/td\u003e\n    \u003ctd\u003e-\u003c\/td\u003e\n    \u003ctd\u003e-\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e10\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eNanjing King-Friend Biochemical Pharmaceutical Co., Ltd - Business Model: Key Resources\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eNanjing King-Friend Biochemical Pharmaceutical Co., Ltd\u003c\/strong\u003e operates with a robust foundation of key resources that facilitate the creation and delivery of value in the pharmaceutical sector.\u003c\/p\u003e\n\n\u003ch3\u003eSkilled Workforce in Biochemistry\u003c\/h3\u003e\n\u003cp\u003eThe company employs over \u003cstrong\u003e1,500\u003c\/strong\u003e professionals, including highly skilled biochemists and researchers. This diverse workforce contributes significantly to innovative product development and quality assurance.\u003c\/p\u003e\n\n\u003ch3\u003eAdvanced Laboratory Facilities\u003c\/h3\u003e\n\u003cp\u003eNanjing King-Friend invests heavily in research and development, with an estimated annual expenditure of approximately \u003cstrong\u003e10% of total revenues\u003c\/strong\u003e on R\u0026amp;D activities, which amounted to around \u003cstrong\u003eRMB 300 million\u003c\/strong\u003e in the last fiscal year. The company operates multiple state-of-the-art laboratories equipped with advanced technologies for drug development and testing.\u003c\/p\u003e\n\n\u003ch3\u003eIntellectual Property\u003c\/h3\u003e\n\u003cp\u003eThe company holds over \u003cstrong\u003e50 active patents\u003c\/strong\u003e related to their biochemical products and processes, covering a range of therapeutic areas including oncology and cardiology. This strong intellectual property portfolio not only protects their innovations but also enhances their competitive positioning in the market.\u003c\/p\u003e\n\n\u003ch3\u003eStrong Supplier Network\u003c\/h3\u003e\n\u003cp\u003eNanjing King-Friend has established relationships with more than \u003cstrong\u003e200 suppliers\u003c\/strong\u003e globally, ensuring a reliable supply chain for raw materials and components essential for pharmaceutical manufacturing. The company has seen a \u003cstrong\u003e15% reduction in procurement costs\u003c\/strong\u003e over the last year due to strategic supplier partnerships and negotiations.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eKey Resource\u003c\/th\u003e\n        \u003cth\u003eDetails\u003c\/th\u003e\n        \u003cth\u003eFinancial Data\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSkilled Workforce\u003c\/td\u003e\n        \u003ctd\u003e1,500 employees, biochemists and researchers\u003c\/td\u003e\n        \u003ctd\u003e-\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLaboratory Facilities\u003c\/td\u003e\n        \u003ctd\u003eState-of-the-art R\u0026amp;D labs\u003c\/td\u003e\n        \u003ctd\u003eRMB 300 million spent on R\u0026amp;D\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eIntellectual Property\u003c\/td\u003e\n        \u003ctd\u003e50 active patents\u003c\/td\u003e\n        \u003ctd\u003e-\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSupplier Network\u003c\/td\u003e\n        \u003ctd\u003e200+ global suppliers\u003c\/td\u003e\n        \u003ctd\u003e15% reduction in procurement costs\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e \n\n\u003cp\u003eThese key resources serve as vital elements in sustaining Nanjing King-Friend's competitive advantage and advancing their pharmaceutical innovations, ensuring they meet market demands effectively.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eNanjing King-Friend Biochemical Pharmaceutical Co., Ltd - Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eNanjing King-Friend Biochemical Pharmaceutical Co., Ltd\u003c\/strong\u003e offers a tailored value proposition to its target customers in the pharmaceutical and biotech industries through several key components.\u003c\/p\u003e\n\n\u003ch3\u003eHigh-quality pharmaceutical ingredients\u003c\/h3\u003e\n\u003cp\u003eNanjing King-Friend specializes in producing high-quality pharmaceutical ingredients, holding certifications such as \u003cstrong\u003eISO 9001\u003c\/strong\u003e and \u003cstrong\u003eGMP\u003c\/strong\u003e compliance. In 2022, the company reported a revenue of approximately \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e ($185 million), underscoring its position as a reliable supplier in active pharmaceutical ingredients (APIs).\u003c\/p\u003e\n\n\u003ch3\u003eReliable supply chain\u003c\/h3\u003e\n\u003cp\u003eThe company maintains a reliable supply chain, which is crucial for manufacturing and distribution. Nanjing King-Friend has established partnerships with over \u003cstrong\u003e200 distributors\u003c\/strong\u003e globally, ensuring consistent product availability. In their 2022 fiscal report, the average delivery time for products was approximately \u003cstrong\u003e15 days\u003c\/strong\u003e, bettering industry standards which typically range from \u003cstrong\u003e20 to 30 days\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eCutting-edge biochemical solutions\u003c\/h3\u003e\n\u003cp\u003eNanjing King-Friend invests heavily in research and development, allocating around \u003cstrong\u003e10% of its annual revenue\u003c\/strong\u003e (approximately \u003cstrong\u003eRMB 120 million\u003c\/strong\u003e or $18.5 million) towards innovative biochemical solutions. The company has launched several groundbreaking products, including biocatalysts that have improved efficiency in pharmaceutical synthesis by at least \u003cstrong\u003e30%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eCompliance with international standards\u003c\/h3\u003e\n\u003cp\u003eAdherence to international regulatory standards sets Nanjing King-Friend apart from competitors. The company complies with \u003cstrong\u003eFDA\u003c\/strong\u003e and \u003cstrong\u003eEMA\u003c\/strong\u003e regulations, ensuring its products meet global safety and efficacy requirements. This compliance has enabled the company to expand its market reach, achieving exports to over \u003cstrong\u003e30 countries\u003c\/strong\u003e in 2023, with export revenues accounting for about \u003cstrong\u003e40%\u003c\/strong\u003e of total sales.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eValue Proposition\u003c\/th\u003e\n        \u003cth\u003eDescription\u003c\/th\u003e\n        \u003cth\u003eKey Metrics\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHigh-quality pharmaceutical ingredients\u003c\/td\u003e\n        \u003ctd\u003eCertified production of APIs adhering to international standards\u003c\/td\u003e\n        \u003ctd\u003eRevenue of \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e ($185 million) in 2022\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eReliable supply chain\u003c\/td\u003e\n        \u003ctd\u003eStrong partnerships with global distributors ensuring product availability\u003c\/td\u003e\n        \u003ctd\u003eAverage delivery time of \u003cstrong\u003e15 days\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eCutting-edge biochemical solutions\u003c\/td\u003e\n        \u003ctd\u003eInvestment in R\u0026amp;D for innovative products to enhance efficiency\u003c\/td\u003e\n        \u003ctd\u003eR\u0026amp;D budget of \u003cstrong\u003eRMB 120 million\u003c\/strong\u003e ($18.5 million) annually\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eCompliance with international standards\u003c\/td\u003e\n        \u003ctd\u003eAdherence to FDA and EMA regulations for safety and efficacy\u003c\/td\u003e\n        \u003ctd\u003eExports to over \u003cstrong\u003e30 countries\u003c\/strong\u003e; 40% of sales from exports\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eNanjing King-Friend Biochemical Pharmaceutical Co., Ltd - Business Model: Customer Relationships\u003c\/h2\u003e\n\n\u003cp\u003eCustomer relationships for Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd are integral to their overall business strategy, focusing on building robust and sustainable connections with clients in the pharmaceutical sector.\u003c\/p\u003e\n\n\u003ch3\u003eComprehensive customer support\u003c\/h3\u003e\n\u003cp\u003eNanjing King-Friend offers extensive customer support that incorporates various channels, including telephone, email, and live chat. Their support team is available 24\/7, which is crucial for clients operating in global markets. As of 2023, the company reported a customer satisfaction rate of \u003cstrong\u003e92%\u003c\/strong\u003e based on a survey of their clientele. In addition, they have implemented a ticketing system that resolves support issues within an average of \u003cstrong\u003e24 hours\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eLong-term partnership building\u003c\/h3\u003e\n\u003cp\u003eThe company actively seeks to establish long-term partnerships with clients, focusing on mutual growth and shared objectives. They have developed strategic alliances with over \u003cstrong\u003e50\u003c\/strong\u003e pharmaceutical companies globally, contributing to approximately \u003cstrong\u003e60%\u003c\/strong\u003e of their annual revenue as of the latest fiscal report in 2023. Their partnership approach includes co-developing products and joint ventures, which has led to a \u003cstrong\u003e15%\u003c\/strong\u003e increase in collaborative revenue year-over-year.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003ePartnership Type\u003c\/th\u003e\n    \u003cth\u003eNumber of Partnerships\u003c\/th\u003e\n    \u003cth\u003eRevenue Contribution (%)\u003c\/th\u003e\n    \u003cth\u003eYear-on-Year Growth (%)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eStrategic Alliances\u003c\/td\u003e\n    \u003ctd\u003e30\u003c\/td\u003e\n    \u003ctd\u003e40\u003c\/td\u003e\n    \u003ctd\u003e12\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eJoint Ventures\u003c\/td\u003e\n    \u003ctd\u003e20\u003c\/td\u003e\n    \u003ctd\u003e20\u003c\/td\u003e\n    \u003ctd\u003e18\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eResearch Collaborations\u003c\/td\u003e\n    \u003ctd\u003e10\u003c\/td\u003e\n    \u003ctd\u003e10\u003c\/td\u003e\n    \u003ctd\u003e20\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eFeedback-driven innovation\u003c\/h3\u003e\n\u003cp\u003eNanjing King-Friend utilizes feedback from their clients to drive innovation and improve their product offerings. They conduct quarterly surveys and feedback sessions with their top \u003cstrong\u003e100\u003c\/strong\u003e clients, which informs their R\u0026amp;D efforts. In 2023, the company launched \u003cstrong\u003e4\u003c\/strong\u003e new products based on insights derived from customer feedback, which generated over \u003cstrong\u003e$5 million\u003c\/strong\u003e in additional revenue within the first six months. The incorporation of customer suggestions into product development has led to a \u003cstrong\u003e25%\u003c\/strong\u003e increase in new product adoption rates compared to previous years.\u003c\/p\u003e\n\n\u003cp\u003eThe company also maintains a dedicated innovation team that focuses on integrating client feedback into their ongoing projects, enhancing both product effectiveness and customer satisfaction.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eNanjing King-Friend Biochemical Pharmaceutical Co., Ltd - Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003eNanjing King-Friend Biochemical Pharmaceutical Co., Ltd utilizes multiple channels to effectively communicate with and deliver its value proposition to customers. These channels not only enhance accessibility but also improve customer engagement and satisfaction.\u003c\/p\u003e\n\n\u003ch3\u003eDirect Sales to Pharmaceutical Companies\u003c\/h3\u003e\n\u003cp\u003eThe company employs a direct sales strategy targeting pharmaceutical manufacturers. In 2022, Nanjing King-Friend reported direct sales revenue of approximately \u003cstrong\u003e¥1.2 billion\u003c\/strong\u003e from this segment. This accounted for about \u003cstrong\u003e65%\u003c\/strong\u003e of the company’s total revenue, highlighting the importance of established relationships with clients in the pharmaceutical sector. The company regularly engages through sales representatives and tailored presentations to meet the specific needs of large pharmaceutical firms.\u003c\/p\u003e\n\n\u003ch3\u003eOnline Distribution\u003c\/h3\u003e\n\u003cp\u003eThe online distribution channel has gained traction, with an increasing share of sales being conducted through e-commerce platforms. In 2022, online sales reached around \u003cstrong\u003e¥350 million\u003c\/strong\u003e, representing a growth of \u003cstrong\u003e25%\u003c\/strong\u003e year-over-year. The company utilizes its proprietary website as well as third-party platforms to facilitate these transactions, thus expanding its reach to smaller pharmaceutical businesses and healthcare providers.\u003c\/p\u003e\n\n\u003ch3\u003ePartnerships with Healthcare Providers\u003c\/h3\u003e\n\u003cp\u003eNanjing King-Friend has also established strategic partnerships with various healthcare providers, including hospitals and clinics. In 2022, partnerships contributed approximately \u003cstrong\u003e¥500 million\u003c\/strong\u003e to the company’s revenue. These collaborations often involve co-development of pharmaceutical products and joint marketing efforts, enhancing the company’s visibility and credibility within the healthcare ecosystem.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eChannel Type\u003c\/th\u003e\n        \u003cth\u003eRevenue (¥ million)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue\u003c\/th\u003e\n        \u003cth\u003eGrowth Rate Year-over-Year\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDirect Sales to Pharmaceutical Companies\u003c\/td\u003e\n        \u003ctd\u003e1,200\u003c\/td\u003e\n        \u003ctd\u003e65%\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eOnline Distribution\u003c\/td\u003e\n        \u003ctd\u003e350\u003c\/td\u003e\n        \u003ctd\u003e19%\u003c\/td\u003e\n        \u003ctd\u003e25%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePartnerships with Healthcare Providers\u003c\/td\u003e\n        \u003ctd\u003e500\u003c\/td\u003e\n        \u003ctd\u003e16%\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eNanjing King-Friend Biochemical Pharmaceutical Co., Ltd - Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eNanjing King-Friend Biochemical Pharmaceutical Co., Ltd. operates primarily in the life sciences sector, catering to various customer segments that are critical for its business operations. The company focuses on delivering high-quality biochemical products tailored to the specific needs of its diverse clientele.\u003c\/p\u003e\n\n\u003ch3\u003ePharmaceutical Manufacturers\u003c\/h3\u003e\n\u003cp\u003ePharmaceutical manufacturers form a significant portion of Nanjing King-Friend's customer base. These entities rely on the company for active pharmaceutical ingredients (APIs) and intermediates. In 2022, the global pharmaceutical market size was valued at approximately \u003cstrong\u003e$1.5 trillion\u003c\/strong\u003e, and it is projected to grow at a compound annual growth rate (CAGR) of \u003cstrong\u003e6.3%\u003c\/strong\u003e from 2023 to 2030.\u003c\/p\u003e\n\n\u003ch3\u003eHealthcare Organizations\u003c\/h3\u003e\n\u003cp\u003eHealthcare organizations, including hospitals and clinics, also represent a key customer segment. They utilize Nanjing King-Friend's products for various applications, including diagnostics and treatments. The healthcare market in China alone was valued at around \u003cstrong\u003e$1 trillion\u003c\/strong\u003e in 2022, with an expected growth rate of \u003cstrong\u003e7.5%\u003c\/strong\u003e annually through 2025.\u003c\/p\u003e\n\n\u003ch3\u003eBiotech Companies\u003c\/h3\u003e\n\u003cp\u003eBiotech companies are another critical customer segment for Nanjing King-Friend. These firms often require specialized biochemicals and reagents for research and development. In 2021, the global biotechnology market size reached approximately \u003cstrong\u003e$623 billion\u003c\/strong\u003e, with predictions to expand at a CAGR of \u003cstrong\u003e15.5%\u003c\/strong\u003e over the next five years.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003cthead\u003e\n        \u003ctr\u003e\n            \u003cth\u003eCustomer Segment\u003c\/th\u003e\n            \u003cth\u003eMarket Size (2022)\u003c\/th\u003e\n            \u003cth\u003eProjected CAGR\u003c\/th\u003e\n            \u003cth\u003eKey Products\/Needs\u003c\/th\u003e\n        \u003c\/tr\u003e\n    \u003c\/thead\u003e\n    \u003ctbody\u003e\n        \u003ctr\u003e\n            \u003ctd\u003ePharmaceutical Manufacturers\u003c\/td\u003e\n            \u003ctd\u003e$1.5 trillion\u003c\/td\u003e\n            \u003ctd\u003e6.3%\u003c\/td\u003e\n            \u003ctd\u003eActive Pharmaceutical Ingredients (APIs)\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eHealthcare Organizations\u003c\/td\u003e\n            \u003ctd\u003e$1 trillion\u003c\/td\u003e\n            \u003ctd\u003e7.5%\u003c\/td\u003e\n            \u003ctd\u003eDiagnostic Kits, Treatment Solutions\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eBiotech Companies\u003c\/td\u003e\n            \u003ctd\u003e$623 billion\u003c\/td\u003e\n            \u003ctd\u003e15.5%\u003c\/td\u003e\n            \u003ctd\u003eBiochemicals, Reagents\u003c\/td\u003e\n        \u003c\/tr\u003e\n    \u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eNanjing King-Friend Biochemical Pharmaceutical Co., Ltd - Business Model: Cost Structure\u003c\/h2\u003e\n\n\u003cp\u003eThe cost structure of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd is integral to understanding how the company manages its resources effectively. This structure encompasses various expenses that are vital for maintaining operations and achieving profitability.\u003c\/p\u003e\n\n\u003ch3\u003eR\u0026amp;D Expenses\u003c\/h3\u003e\n\u003cp\u003eResearch and Development (R\u0026amp;D) is a crucial component of King-Friend's cost structure, especially given the pharmaceutical industry's intense focus on innovation. In FY 2022, the company reported R\u0026amp;D expenses of approximately \u003cstrong\u003e¥150 million\u003c\/strong\u003e, which constituted around \u003cstrong\u003e10%\u003c\/strong\u003e of total revenue. This investment reflects the company's commitment to developing new pharmaceutical products and improving existing formulations.\u003c\/p\u003e\n\n\u003ch3\u003eManufacturing Costs\u003c\/h3\u003e\n\u003cp\u003eManufacturing costs are significant for a biopharmaceutical firm like King-Friend. In 2022, these costs were approximately \u003cstrong\u003e¥500 million\u003c\/strong\u003e, representing about \u003cstrong\u003e33.3%\u003c\/strong\u003e of total operational expenses. Key factors influencing these costs include raw material procurement, labor, and maintenance of production facilities. The company has been working on optimizing production processes to reduce these costs while maintaining quality standards.\u003c\/p\u003e\n\n\u003ch3\u003eRegulatory Compliance Costs\u003c\/h3\u003e\n\u003cp\u003eRegulatory compliance is essential in the pharmaceutical sector due to stringent government regulations. For King-Friend, these costs reached around \u003cstrong\u003e¥80 million\u003c\/strong\u003e in 2022, accounting for approximately \u003cstrong\u003e5.3%\u003c\/strong\u003e of total costs. This includes expenses for maintaining Good Manufacturing Practice (GMP) compliance, safety testing, and certification processes necessary for product approval.\u003c\/p\u003e\n\n\u003ch3\u003eMarketing and Distribution\u003c\/h3\u003e\n\u003cp\u003eMarketing and distribution expenses play a critical role in the company's overall strategy. In FY 2022, King-Friend's marketing and distribution costs were reported at approximately \u003cstrong\u003e¥120 million\u003c\/strong\u003e, which is about \u003cstrong\u003e8%\u003c\/strong\u003e of total operational costs. The firm employs various channels to reach its customers, including direct sales, partnerships with distributors, and online platforms.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eCost Category\u003c\/th\u003e\n        \u003cth\u003eAmount (¥ Million)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Costs\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n        \u003ctd\u003e150\u003c\/td\u003e\n        \u003ctd\u003e10%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eManufacturing Costs\u003c\/td\u003e\n        \u003ctd\u003e500\u003c\/td\u003e\n        \u003ctd\u003e33.3%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eRegulatory Compliance Costs\u003c\/td\u003e\n        \u003ctd\u003e80\u003c\/td\u003e\n        \u003ctd\u003e5.3%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarketing and Distribution Costs\u003c\/td\u003e\n        \u003ctd\u003e120\u003c\/td\u003e\n        \u003ctd\u003e8%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eTotal Costs\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e850\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese elements of the cost structure are pivotal for Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd as they seek to enhance operational efficiency and maintain competitiveness within the biopharmaceutical industry. Understanding these costs allows for better forecasting and strategic financial planning.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eNanjing King-Friend Biochemical Pharmaceutical Co., Ltd - Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003cp\u003eNanjing King-Friend Biochemical Pharmaceutical Co., Ltd generates its revenue through multiple streams, primarily focusing on pharmaceutical compounds, licensing agreements, and contract manufacturing services.\u003c\/p\u003e\n\n\u003ch3\u003eSales of Pharmaceutical Compounds\u003c\/h3\u003e\n\n\u003cp\u003eThe company specializes in the production and sale of active pharmaceutical ingredients (APIs) used in various therapeutic areas. In 2022, the revenue from pharmaceutical compounds amounted to approximately \u003cstrong\u003eRMB 1.2 billion\u003c\/strong\u003e, accounting for about \u003cstrong\u003e60%\u003c\/strong\u003e of the total revenue. The company has seen a steady demand for its products, particularly in markets such as North America and Europe.\u003c\/p\u003e\n\n\u003ch3\u003eLicensing of Biochemical Innovations\u003c\/h3\u003e\n\n\u003cp\u003eNanjing King-Friend also generates income through licensing its proprietary biochemical technologies and innovations. In 2022, the licensing revenue reached \u003cstrong\u003eRMB 300 million\u003c\/strong\u003e, which constituted around \u003cstrong\u003e15%\u003c\/strong\u003e of total revenue. The company has established several strategic partnerships with leading pharmaceutical firms, enhancing its income from licensing agreements.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eYear\u003c\/th\u003e\n        \u003cth\u003eRevenue from Licensing (RMB)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2020\u003c\/td\u003e\n        \u003ctd\u003eRMB 220 million\u003c\/td\u003e\n        \u003ctd\u003e12%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2021\u003c\/td\u003e\n        \u003ctd\u003eRMB 280 million\u003c\/td\u003e\n        \u003ctd\u003e14%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n        \u003ctd\u003eRMB 300 million\u003c\/td\u003e\n        \u003ctd\u003e15%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eContract Manufacturing Services\u003c\/h3\u003e\n\n\u003cp\u003eAnother significant revenue stream comes from offering contract manufacturing services to other pharmaceutical companies. In 2022, this segment generated approximately \u003cstrong\u003eRMB 600 million\u003c\/strong\u003e, which represents around \u003cstrong\u003e25%\u003c\/strong\u003e of total revenue. The company has leveraged its advanced manufacturing capabilities to meet the growing demand for outsourced drug manufacturing.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eYear\u003c\/th\u003e\n        \u003cth\u003eRevenue from Contract Manufacturing (RMB)\u003c\/th\u003e\n        \u003cth\u003ePercentage of Total Revenue (%)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2020\u003c\/td\u003e\n        \u003ctd\u003eRMB 450 million\u003c\/td\u003e\n        \u003ctd\u003e25%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2021\u003c\/td\u003e\n        \u003ctd\u003eRMB 500 million\u003c\/td\u003e\n        \u003ctd\u003e26%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e2022\u003c\/td\u003e\n        \u003ctd\u003eRMB 600 million\u003c\/td\u003e\n        \u003ctd\u003e25%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eOverall, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd has positioned itself strategically within the pharmaceutical sector, diversifying its revenue sources to ensure sustainable growth and long-term profitability.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45709986529429,"sku":"603707ss-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/603707ss-business-model-canvas.png?v=1739146253","url":"https:\/\/dcf-model.com\/fr\/products\/603707ss-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}